Karius has raised USD 100 million in Series C funding co-led by Khosla Ventures and new investors 5AM Ventures and Gilde Healthcare, with participation from Seventure Partners, Softbank Vision Fund 2, General Catalyst, HBM Healthcare Investments, Blue Water Life Sciences, Innovation Endeavors, and Waycross Ventures.

The funds are expected to address the demand for its proprietary Karius Test—expanding beyond its current reach of 400 US hospitals—and to facilitate research exploring the wider health implications of Karius' microbial cell-free DNA technology beyond infectious ailments.

Karius operates in the life sciences sector, focusing on infectious disease diagnostics through genomic insights. Its Karius Test is a liquid biopsy test that non-invasively detects ~1,000 pathogens from a single blood sample. This test uses advanced genomics and AI to analyze microbial cell-free DNA, providing diagnostic information that enables rapid treatment decisions.